case_images: PMC9464026_01
case_images: MRI brain results for Case 1 and 2 pre- and post-daratumumab therapy. (A) Case 1: Brain MRI taken 1 month prior to initiation of daratumumab. Note the thin subdural hematoma and mild ischemic changes. (B) Case 1: Brain MRI taken 13 months after initiation of daratumumab showed abnormal T2 signal seen in bilateral frontal regions and right temporal lobe, with microvascular ischemic and resolved hematoma. (C) Case 2: Baseline brain MRI without contrast taken 34 months prior to initiation of daratumumab showed mild microvascular ischemic changes. (D) Case 2: Brain MRI taken 9 months after initiating daratumumab showed mild interval increases in ventriculomegaly and extensive bilateral confluent foci of increased T2-FLAIR changes within the cerebral white matter.
case_images: OTT-15-953-g0001.jpg
case_images: PMC9464026_02_OTT-15-953-g0001.jpg
case_images: f0001
case_images: April 2016 (Figure 1C); mild microvascular ischemic changes were seen, but the results were otherwise unremarkable. After disease progression in late 2016, he was prescribed ixazomib, pomalidomide, and dexamethasone (IPd). Assessment [MoCA] score of 24/30) and diffuse hyperreflexia. A brain MRI was performed in November 2019 (Figure 1D) and showed mild interval increases in ventriculomegaly and extensive bilateral confluent foci of increased T2-FLAIR changes within the cerebral white matter, with some microvascular ischemic changes.
case_images: PMC9464026_02
case_images: MRI brain results for Case 1 and 2 pre- and post-daratumumab therapy. (A) Case 1: Brain MRI taken 1 month prior to initiation of daratumumab. Note the thin subdural hematoma and mild ischemic changes. (B) Case 1: Brain MRI taken 13 months after initiation of daratumumab showed abnormal T2 signal seen in bilateral frontal regions and right temporal lobe, with microvascular ischemic and resolved hematoma. (C) Case 2: Baseline brain MRI without contrast taken 34 months prior to initiation of daratumumab showed mild microvascular ischemic changes. (D) Case 2: Brain MRI taken 9 months after initiating daratumumab showed mild interval increases in ventriculomegaly and extensive bilateral confluent foci of increased T2-FLAIR changes within the cerebral white matter.
case_images: OTT-15-953-g0001.jpg
case_images: PMC9464026_02_OTT-15-953-g0001.jpg
case_images: f0001
case_images: April 2016 (Figure 1C); mild microvascular ischemic changes were seen, but the results were otherwise unremarkable. After disease progression in late 2016, he was prescribed ixazomib, pomalidomide, and dexamethasone (IPd). Assessment [MoCA] score of 24/30) and diffuse hyperreflexia. A brain MRI was performed in November 2019 (Figure 1D) and showed mild interval increases in ventriculomegaly and extensive bilateral confluent foci of increased T2-FLAIR changes within the cerebral white matter, with some microvascular ischemic changes.